Last updated: May 18, 2026
What BPC-157 is
BPC-157 is a synthetic peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. First synthesized and characterized in the early 1990s by Predrag Sikiric’s research group at the University of Zagreb, which has published over 100 peer-reviewed papers on it.
Unusually for short peptides, BPC-157 is reported to retain biological activity after oral administration — meaning it survives gastric acidic conditions. This is a primary differentiator vs most therapeutic peptides which must be injected.
Mechanism of action
BPC-157’s mechanism is not fully characterized but published research points to multiple pathways:
- Nitric oxide system modulation: upregulates eNOS in damaged tissue, modulates the L-arginine/NO pathway
- Angiogenesis: stimulates VEGFR2 expression, promoting new blood vessel formation at injury sites
- Growth factor effects: upregulates growth hormone receptor expression in tendon, accelerates fibroblast migration
- Brain-gut axis: neuroprotective effects in TBI, stroke, serotonin syndrome models
- Cytoprotection: reduces gastric damage from NSAIDs, alcohol, and various toxins
Research applications
Tendon and ligament repair
The most-cited application. Rodent studies show accelerated healing of transected Achilles tendons, with restoration of mechanical strength faster than controls. Similar findings in medial collateral ligament and quadriceps muscle transection models.
Gut health
Strong evidence in rodent models for protection against NSAID-induced ulcers, ethanol-induced gastric damage, TNBS-induced colitis, and short bowel syndrome adaptation.
Muscle injury
Crush injury and laceration models show faster restoration of contractile function and morphology with BPC-157 treatment.
Neuroprotection
TBI, stroke, and encephalopathy models show reduced lesion size and improved behavioral recovery.
Reported dosing protocols (research only)
Doses used in published rodent research vary by route. Commonly cited research-community protocols for subcutaneous human use range from 200-500 µg per day, divided into 1-2 doses, for 4-6 weeks. These protocols do not represent FDA-approved or clinical dosing guidance.
Safety profile
Rodent toxicology studies show no observed toxicity at doses thousands of times higher than effective doses. No teratogenicity, carcinogenicity, or organ damage reported.
Caveats: All toxicology data is rodent. Long-term human safety is unknown. Reports from research-community use describe occasional injection-site reactions and transient headache.
Regulatory status (2026)
- US: Sold as a research peptide; not FDA-approved for any human indication
- WADA: Banned for competitive athletes since January 2022 (S0 non-approved substances)
- Australia (TGA): Schedule 10 (prohibited for human use) since 2022
- EU: Not approved as a medicine; research-chemical sale varies by country
Does BPC-157 actually work in humans?<br />
No published human clinical trials exist as of 2026. All efficacy data is from rodent and in vitro studies. Anecdotal reports from research-community use are positive but not equivalent to clinical evidence.
How is BPC-157 administered?<br />
Most research uses subcutaneous or intraperitoneal injection. Oral administration is also studied (the peptide is reported to be gastric-stable).
How long until effects show?<br />
Published rodent research typically shows measurable tissue-repair benefits within 4-14 days of administration.
Can BPC-157 be stacked with TB-500?<br />
Common pairing in research-community use based on a hypothesis that BPC-157 promotes angiogenesis while TB-500 promotes cell migration. No published clinical or animal study directly testing the combination.